Which weight-loss medication class should be avoided in patients with cardiovascular disease?

Which weight-loss medication class should be avoided in patients with cardiovascular disease?

• A. Orlistat
• B. Sympathomimetics
• C. Topiramate
• D. Naltrexone/Bupropion

Answer: (B)

The main concept is that drugs which stimulate the sympathetic nervous system can worsen heart disease. Weight‑loss medications that are sympathomimetics increase heart rate and blood pressure and raise the heart’s work, which can trigger angina, arrhythmias, or even ischemic events in patients with cardiovascular disease. For this reason, this class is avoided in people with heart conditions, since the potential cardiovascular risks outweigh the weight‑loss benefits. Other options work differently. Orlistat blocks fat absorption in the gut and has little systemic cardiovascular impact, so it’s not primarily limited by heart disease. Topiramate promotes weight loss through central mechanisms without stimulating the heart. Naltrexone/bupropion has some cardiovascular effects and is used with caution in cardiovascular disease, but it does not carry the same direct sympathomimetic risk as the stimulant class.

The main concept is that drugs which stimulate the sympathetic nervous system can worsen heart disease. Weight‑loss medications that are sympathomimetics increase heart rate and blood pressure and raise the heart’s work, which can trigger angina, arrhythmias, or even ischemic events in patients with cardiovascular disease. For this reason, this class is avoided in people with heart conditions, since the potential cardiovascular risks outweigh the weight‑loss benefits.

Other options work differently. Orlistat blocks fat absorption in the gut and has little systemic cardiovascular impact, so it’s not primarily limited by heart disease. Topiramate promotes weight loss through central mechanisms without stimulating the heart. Naltrexone/bupropion has some cardiovascular effects and is used with caution in cardiovascular disease, but it does not carry the same direct sympathomimetic risk as the stimulant class.